Charles P. Theuer, President and CEO
Dr. Theuer has served as our President, Chief Executive Officer and a member of our board of directors since July 2006. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company, where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. At Pfizer, Dr. Theuer led the clinical development of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer’s previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology.
Bonne Adams, Chief Operating Officer
Ms. Adams joined us as our Vice President of Clinical Operations in August 2006, was promoted to Senior Vice President of Clinical Operations in July 2014, and was promoted to Executive Vice President of Clinical Operations in January 2019. Prior to joining us, Ms. Adams was a Manager of Clinical Operations at Pfizer, Inc., a pharmaceutical corporation, from 2004 to 2006 and at Biogen Idec, Inc., a biotechnology company, from 2002 to 2004. Ms. Adams managed clinical trials at Pfizer that contributed to the 2006 approval of Sutent® in renal cell carcinoma and gastrointestinal stromal tumors, and she managed clinical trials at Biogen Idec that fulfilled post-approval commitments for Zevalin® and Rituxan®. Ms. Adams has managed both early and late-stage oncology studies of small molecules as well as biologics in the areas of lymphoma, lung, colorectal, ovarian, kidney, sarcoma and breast cancers. From 2000 to 2002, she managed non-oncology programs at Quintiles Inc., a service provider for biopharmaceutical and health sciences companies, including studies in the areas of allergy and pulmonary disease. Ms. Adams received a B.A. in Kinesiology and Biology from the University of Colorado and an M.B.A. in Technology Management from The University of Phoenix.
Shahe Garabedian, Senior Vice President
Mr. Garabedian joined us as Senior Vice President and Head of Quality Assurance in 2020. Most recently, he was Vice President of Quality at Arena Pharmaceuticals, and past positions included Vice President of Global Corporate Quality Assurance, Regulatory and Environmental Health Science at Invitrogen, and Executive Director and Head of Quality Assurance at SUGEN Inc. During his career, he has led Quality groups across GLP, GMP and GCP functional areas in the development of compounds in a variety of therapeutic areas, including oncology. Mr. Garabedian received his Bachelor of Science and Master of Science degrees from the University of La Verne.
Brenda Marczi, Senior Vice President
James Freddo, Chief Medical Officer
Dr. Freddo joined TRACON as Chief Medical Officer in May 2020 and brings more than two decades of clinical development and corporate governance experience to TRACON. Previously, Dr. Freddo was Executive Director, Site Therapeutic Area Leader, Clinical Development, Oncology at Pfizer and oversaw development activities culminating in the approvals of Sutent (sunitinib), Inlyta (axitinib) and Xalkori (crizotinib). Following that, he was Chief Medical Officer at Anadys Pharmaceuticals, Inc. until its acquisition by Roche in 2011. Following that, he was Chief Medical Officer and a Board Director at Ignyta, Inc. prior to its acquisition by Roche in 2017. Dr. Freddo holds a B.S. in Medical Technology from the State University of New York at Stony Brook, NY, and a M.D. from the University of North Carolina, Chapel Hill, NC, where he also completed his fellowship training.
Scott B. Brown, Chief Financial Officer
Mr. Brown joined us as Director, Finance and Controller in August 2015, was promoted to Sr. Director, Finance and Controller in January 2017, and was promoted to Vice President, Finance and Head of Finance in January 2019. Prior to joining us, Mr. Brown was Associate Director, Finance at Ardea Biosciences (acquired by AstraZeneca) where he led finance and accounting for Ardea Biosciences as a subsidiary of AstraZeneca from 2013 to 2015. Before that, from 2011 to 2013 Mr. Brown was Finance Manager at SciClone Pharmaceuticals, Inc., and Finance Manager at Exelixis, Inc. from 2009 to 2011. Prior to Exelixis, Mr. Brown held accounting positions of increasing responsibility at AcelRx, Inc., Spinal Elements, Inc., Stewart Title, and as an audit associate for KPMG, LLP. Mr. Brown received a B.S. from the University of California, Santa Barbara, a M.S. in Accountancy from San Diego State University, and is a Certified Public Accountant licensed in the state of California.